Effect of ketamine infusion in treatment resistant depression and in depressive patients with active suicidal ideations: a study from North India

Ubaid Rasool; Neelofer Jan; Marya Zahoor; Fazle Roub; Yasir Hassan Rather; Arshad Hussain; Rukhsana Najeeb

doi:10.18203/2320-6012.ijrms20230029

Authors

Ubaid Rasool Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Neelofer Jan Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Marya Zahoor Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Fazle Roub Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Yasir Hassan Rather Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Arshad Hussain Department of Psychiatry (IMHANS-K), GMC Srinagar, Kashmir, Jammu and Kashmir, India
Rukhsana Najeeb Department of Anaesthesiology, GMC Srinagar, Kashmir, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20230029

Keywords:

Depression, Suicide, Ketamine

Abstract

Background: Treatment resistant depression can be a life-threatening condition as it leads to an increase of suicide attempts by two to three folds. It has been estimated that nearly 1 million people die due to suicide every year, and more than two-third of these cases occur when the person is undergoing a major depressive episode. Ketamine is an NMDA receptor antagonist, an anesthetic agent that is short acting and has recently been used as an antidepressant and anti-suicidal agent. It has been seen that a single intravenous infusion of ketamine at a lower dose. i.e., subanesthetic dose of 0.5 mg/kg over a period of 40 minutes produces antidepressant effect which lasts for about a week and various studies have proved that repeated infusions of ketamine can prolong the duration of the antidepressant response.

Methods: It was an observational/descriptive study done in the ketamine clinic/ECT suite of institute of mental health and neurosciences Kashmir (an associate hospital of government medical college Srinagar) which runs once a week. In this study, patients satisfying the criteria of TRD and depressive patients with active suicidal ideations, visiting the ketamine clinic who had given a valid informed consent for ketamine infusion enrolled and observed for ketamine efficacy by using specific scales. The study done over a period of 18 months from January 2020 till July 2021.

Results: The response rate of ketamine in our study for treatment resistant depression was 70.27%. The response rate of ketamine for suicidality in our study was 63.16%. Our study showed a rapid onset of action for ketamine, two hours after ketamine infusion.

Conclusions: A significant fraction of patients suffering from major depressive disorder do not respond to antidepressants and have a poor psychosocial functioning and an increased risk of suicide attempts making their condition life threatening. These patients therefore require special attention to address their underlying condition as well as suicidality to improve their outcome. In this context we studied the role of intravenous ketamine infusion in these patients in improving the psychosocial outcome as well as preventing the suicidal ideation.

Metrics

Metrics Loading ...

References

Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267-84.

Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020;16:221-34.

Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatr. 2014;26(3):222-32.

Kraus C, Kadriu B, Lanzenberger R. Prognosis and improved outcomes in major depression: a review. Transl Psychiatr. 2019;9:127.

Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606-12.

Carboni Ezio, Carta A R, Carboni Elena, Novelli A. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? Front Nuerosci. 2021;30.

Thakurta RG, Das R, Bhattacharya AK, Saha D, Sen S, Singh OP, Bisui B. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012;34(2):170-5.

Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatr. 2019;61(5):480-5.

Shiroma PR, Thuras P, Wels J. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatr. 2020;10:206.

Chang Lee C, Rajagopalan S, Mathew SJ. History of Ketamine use and its clinical indications. In; Mathew SJ, Zarate Jr CA., editors. Ketamine for treatment resistant depression- the first decade of progress. Switzerland; Springer Nature. 2016;3.

Fourcade EW, Lapidus KAB. The basic and clinical pharmacology of Ketamine. In; Mathew SJ, Zarate Jr CA., editors. Ketamine for treatment resistant depression- the first decade of progress. Switzerland; Springer Nature. 2016;17

Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 4th ed. Cambridge, UK; New York: Cambridge University Press. 2011.

Breseghello CV, Da Costa LP, Luiz LA. Subcutaneous Ketamine in Depression: A Systematic Review. Front Psychiatr. 2021;12.

Blier P, Blier J. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders. In; Mathew SJ, Zarate Jr CA., editors. Ketamine for treatment resistant depression- the first decade of progress. Switzerland; Springer Nature. 2016;31

Lee B, Mark AB. Handbook of clinical rating scales and assessment in psychiatry and mental health. 1st ed. Boston USA, Springer. 2010;8-13.

Singh JB, Maggie F. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients with Treatment-Resistant Depression. Am J Psychiatr. 2016;173(8):816-26.

Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536-44.

Choi H, Marks NF. Marital Conflict, Depressive Symptoms, and Functional Impairment. J Marriage Fam. 2008;70(2):377-390.

Woo JM, Postolache TT. The impact of work environment on mood disorders and suicide: Evidence and implications. Int J Disabil Hum Dev. 2008;7(2):185-200.

Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan het Rot M, Collins KA et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatr. 2013;74(4):250-6.

Ajaz A, Sajid MW, Abdul WK. Socio-demographic and clinical profile of patients with major depressive disorder attending psychiatric OPD. JMSCR. 2020;8(5):197-205.

Bellard ED, Price RB. Ketamine and suicide risk. In; Mathew SJ, Zarate Jr CA, editors. Ketamine for treatment resistant depression- the first decade of progress. Switzerland; Springer Nature. 2016;46

Lener MS, Kadriu B, Zarate CA Jr. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs. 2017;77(4):381-401.

Zarate CA, Singh JB, Carlson PJ. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Arch Gen Psychiatr. 2006;63(8):856-64.

Ji-Chun Z, Su-xia L, Hashimoto K. R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137-41.

Rota MH, Collins KA. Mathewa Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. Biol Psychiatr. 2010;67(2):139-45.

Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161-6.

Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Mental Health. 2016;19(2):35-8.